Wim J G Oyen

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1550100/wim-j-g-oyen-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

506	26,817	78	140
papers	citations	h-index	g-index
532 ext. papers	30,552 ext. citations	6.4 avg, IF	6.73 L-index

#	Paper	IF	Citations
506	[F]FDG-PET/CT to prevent futile surgery in indeterminate thyroid nodules: a blinded, randomised controlled multicentre trial European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 197	08.8	4
505	Quantitative classification and radiomics of [F]FDG-PET/CT in indeterminate thyroid nodules <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022 , 1	8.8	2
504	18F-FDG PET-CT scanning in rheumatoid arthritis patients tapering TNFi: reliability, validity and predictive value. <i>Rheumatology</i> , 2021 ,	3.9	2
503	Nuclear medicine theranostics comes of age. <i>Lancet Oncology, The</i> , 2021 , 22, 1497-1498	21.7	3
502	Consensus on molecular imaging and theranostics in neuroendocrine neoplasms. <i>European Journal of Cancer</i> , 2021 , 146, 56-73	7.5	32
501	Medical imaging and nuclear medicine: a Lancet Oncology Commission. <i>Lancet Oncology, The</i> , 2021 , 22, e136-e172	21.7	39
500	A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the European Thyroid Association, the Society of Nuclear Medicine and Molecular Imaging on Current Diagnostic and Theranostic Approaches in the Management of Thyroid Cancer.	6.2	7
499	Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021 , 48, 469-476	8.8	42
498	Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation. <i>Cancers</i> , 2021 , 13,	6.6	1
497	Prospective Evaluation of Whole-Body MRI versus FDG PET/CT for Lesion Detection in Participants with Myeloma. <i>Radiology Imaging Cancer</i> , 2021 , 3, e210048	1.4	1
496	Follow-up imaging after cryoablation of clear cell renal cell carcinoma is feasible using single photon emission computed tomography with In-girentuximab. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020 , 47, 1864-1870	8.8	1
495	Amyloid-PET and F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology, The</i> , 2020 , 19, 951-962	24.1	95
494	A Clinical Feasibility Study to Image Angiogenesis in Patients with Arteriovenous Malformations Using Ga-RGD PET/CT. <i>Journal of Nuclear Medicine</i> , 2020 , 61, 270-275	8.9	3
493	Lesion detection by [Zr]Zr-DFO-girentuximab and [F]FDG-PET/CT in patients with newly diagnosed metastatic renal cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 1931-1939	8.8	25
492	Molecular Imaging and Theranostics-A Multidisciplinary Approach. <i>Seminars in Nuclear Medicine</i> , 2019 , 49, 247-254	5.4	13
491	Early Metabolic Response as a Predictor of Treatment Outcome in Patients With Metastatic Soft Tissue Sarcomas. <i>Anticancer Research</i> , 2019 , 39, 1309-1316	2.3	5
490	Tumor to cervical spinal cord standardized uptake ratio (SUR) improves the reproducibility of F-FDG-PET based tumor segmentation in head and neck squamous cell carcinoma in a multicenter setting. <i>Radiotherapy and Oncology</i> , 2019 , 130, 39-45	5.3	3

489	Managing Nonmetastatic Castration-resistant Prostate Cancer. European Urology, 2019, 75, 285-293	10.2	83
488	Imaging Diagnosis and Follow-up of Advanced Prostate Cancer: Clinical Perspectives and State of the Art. <i>Radiology</i> , 2019 , 292, 273-286	20.5	24
487	Consensus Procedures in Oncological Imaging: The Case of Prostate Cancer. Cancers, 2019, 11,	6.6	2
486	The EANM practical guidelines for sentinel lymph node localisation in oral cavity squamous cell carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 623-637	8.8	51
485	Diagnostic Utility of Molecular and Imaging Biomarkers in Cytological Indeterminate Thyroid Nodules. <i>Endocrine Reviews</i> , 2018 , 39, 154-191	27.2	28
484	In Vivo Characterization of 4 Ga-Labeled Multimeric RGD Peptides to Image Integrin Expression in 2 Human Tumor Xenograft Mouse Models. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 1296-1301	8.9	19
483	F-FDG PET/CT in Local Ablative Therapies: A Systematic Review. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 551-556	8.9	9
482	The diagnostic value of F-FDG-PET/CT and MRI in suspected vertebral osteomyelitis - a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 798-805	8.8	33
481	Positron Emission Tomography/Computed Tomography with Zr-girentuximab Can Aid in Diagnostic Dilemmas of Clear Cell Renal Cell Carcinoma Suspicion. <i>European Urology</i> , 2018 , 74, 257-260	10.2	40
480	. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018 , 2, 33-40	4.2	7
480 479	. IEEE Transactions on Radiation and Plasma Medical Sciences, 2018, 2, 33-40 Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. Clinical Radiology, 2018, 73, 588-589	2.9	7
, i	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and		
479	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2018 , 73, 588-589 HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by	2.9	6
479 478	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2018 , 73, 588-589 HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. <i>Clinical Cancer Research</i> , 2018 , 24, 1853-1865 The Value of F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever.	2.9	6
479 478 477	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2018 , 73, 588-589 HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. <i>Clinical Cancer Research</i> , 2018 , 24, 1853-1865 The Value of F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 127-133 Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. <i>Expert</i>	2.9 12.9 8.9	6 20 18
479 478 477 476	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2018 , 73, 588-589 HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. <i>Clinical Cancer Research</i> , 2018 , 24, 1853-1865 The Value of F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 127-133 Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. <i>Expert Opinion on Drug Delivery</i> , 2018 , 15, 185-196 Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal	2.9 12.9 8.9 8	6 20 18 25
479 478 477 476 475	Diagnostic yield of FDG-PET/CT in fever of unknown origin: a systematic review, meta-analysis, and Delphi exercise. <i>Clinical Radiology</i> , 2018 , 73, 588-589 HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging. <i>Clinical Cancer Research</i> , 2018 , 24, 1853-1865 The Value of F-FDG PET/CT in Diagnosis and During Follow-up in 273 Patients with Chronic Q Fever. <i>Journal of Nuclear Medicine</i> , 2018 , 59, 127-133 Radioimmunotherapy for delivery of cytotoxic radioisotopes: current status and challenges. <i>Expert Opinion on Drug Delivery</i> , 2018 , 15, 185-196 Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study. <i>Theranostics</i> , 2018 , 8, 2161-2170 Early metabolic response as predictor for treatment outcome of pazopanib in patients with	2.9 12.9 8.9 8	6 20 18 25 62

471	Fever of Unknown Origin: the Value of FDG-PET/CT. Seminars in Nuclear Medicine, 2018, 48, 100-107	5.4	68
470	EANM/EARL FDG-PET/CT accreditation - summary results from the first 200 accredited imaging systems. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018 , 45, 412-422	8.8	62
469	Consensus on molecular imaging and theranostics in prostate cancer. <i>Lancet Oncology, The</i> , 2018 , 19, e696-e708	21.7	59
468	18F-fluorodeoxyglucose positron-emission tomography combined with computed tomography as a diagnostic tool in native valve endocarditis. <i>Nuclear Medicine Communications</i> , 2018 , 39, 747-752	1.6	26
467	Vascular infection with outside-in vertebral destruction in chronic Q fever. <i>Lancet Infectious Diseases, The</i> , 2018 , 18, 603	25.5	2
466	A comparison of the diagnostic value of MRI and F-FDG-PET/CT in suspected spondylodiscitis. <i>Infection</i> , 2017 , 45, 41-49	5.8	56
465	Report of the 6th International Workshop on PET in lymphoma. <i>Leukemia and Lymphoma</i> , 2017 , 58, 22	98 <u>1</u> 2303	3 15
464	Radiopharmaceuticals in the elderly cancer patient: Practical considerations, with a focus on prostate cancer therapy: A position paper from the International Society of Geriatric Oncology Task Force. <i>European Journal of Cancer</i> , 2017 , 77, 127-139	7.5	10
463	Tumor Delineation and Quantitative Assessment of Glucose Metabolic Rate within Histologic Subtypes of Non-Small Cell Lung Cancer by Using Dynamic F Fluorodeoxyglucose PET. <i>Radiology</i> , 2017 , 283, 547-559	20.5	6
462	Practical recommendations for radium-223 treatment of metastatic castration-resistant prostate cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1671-1678	8.8	39
461	Guideline for PET/CT imaging of neuroendocrine neoplasms with Ga-DOTA-conjugated somatostatin receptor targeting peptides and F-DOPA. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 1588-1601	8.8	179
460	F-FDG PET/CT Optimizes Treatment in Bacteremia and Is Associated with Reduced Mortality. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1504-1510	8.9	45
459	Uniform FDG-PET guided GRAdient Dose prEscription to reduce late Radiation Toxicity (UPGRADE-RT): study protocol for a randomized clinical trial with dose reduction to the elective neck in head and neck squamous cell carcinoma. <i>BMC Cancer</i> , 2017 , 17, 208	4.8	16
45 ⁸	The Predictive Value of Early In-Treatment F-FDG PET/CT Response to Chemotherapy in Combination with Bevacizumab in Advanced Nonsquamous Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2017 , 58, 1243-1248	8.9	13
457	Response Monitoring with [F]FLT PET and Diffusion-Weighted MRI After Cytotoxic 5-FU Treatment in an Experimental Rat Model for Colorectal Liver Metastases. <i>Molecular Imaging and Biology</i> , 2017 , 19, 540-549	3.8	4
456	Guidelines for quality control of PET/CT scans in a multicenter clinical study. <i>EJNMMI Physics</i> , 2017 , 4, 23	4.4	14
455	Dosimetry in clinical radionuclide therapy: the devil is in the detail. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 44, 2137-9	8.8	24
454	Clinical application of FDG-PET/CT in metastatic infections. <i>Quarterly Journal of Nuclear Medicine and Molecular Imaging</i> , 2017 , 61, 232-246	1.4	6

453 Infectie en ontsteking **2017**, 579-604

452	PET/CT with (11)C-choline for evaluation of prostate cancer patients with biochemical recurrence: meta-analysis and critical review of available data. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2016 , 43, 55-69	8.8	153
451	The Predictive Value of Early Assessment After 1 Cycle of Induction Chemotherapy with 18F-FDG PET/CT and Diffusion-Weighted MRI for Response to Radical Chemoradiotherapy in Head and Neck Squamous Cell Carcinoma. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1843-1850	8.9	38
450	Abscopal effect of radiotherapy in a patient with metastatic diffuse-type giant cell tumor. <i>Acta Oncolgica</i> , 2016 , 55, 1510-1512	3.2	10
449	International Multi-Specialty Delphi Survey: Identification of Diagnostic Criteria for Hepatic and Renal Cyst Infection. <i>Nephron</i> , 2016 , 134, 205-214	3.3	9
448	The Impact of Optimal Respiratory Gating and Image Noise on Evaluation of Intratumor Heterogeneity on 18F-FDG PET Imaging of Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1692-169	8.9	53
447	Monitoring Therapy Response of Experimental Arthritis with Radiolabeled Tracers Targeting Fibroblasts, Macrophages, or Integrin ⊞. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 467-72	8.9	28
446	Phase 2 Study of Lutetium 177-Labeled Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab in Patients with Advanced Renal Cell Carcinoma. <i>European Urology</i> , 2016 , 69, 767-70	10.2	34
445	99mTc-CXCL8 SPECT to Monitor Disease Activity in Inflammatory Bowel Disease. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 398-403	8.9	17
444	Prophylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity. <i>Cancer Immunology, Immunotherapy</i> , 2016 , 65, 327-39	7.4	37
443	Effectiveness of an (18)F-FDG-PET based strategy to optimize the diagnostic trajectory of suspected recurrent laryngeal carcinoma after radiotherapy: The RELAPS multicenter randomized trial. <i>Radiotherapy and Oncology</i> , 2016 , 118, 251-6	5.3	16
442	Molecular imaging as a tool to investigate heterogeneity of advanced HER2-positive breast cancer and to predict patient outcome under trastuzumab emtansine (T-DM1): the ZEPHIR trial. <i>Annals of Oncology</i> , 2016 , 27, 619-24	10.3	195
441	FDG-PET/CT Limited to the Thorax and Upper Abdomen for Staging and Management of Lung Cancer. <i>PLoS ONE</i> , 2016 , 11, e0160539	3.7	
440	18F-FDG PET/CT in Detecting Metastatic Infection in Children. Clinical Nuclear Medicine, 2016 , 41, 278-8	1 _{1.7}	5
439	ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. <i>Annals of Oncology</i> , 2016 , 27, 1386-422	10.3	1683
438	A5.03 Monitoring therapy response of experimental arthritis with radiolabeled tracers targeting fibroblasts, macrophages or integrin III. Annals of the Rheumatic Diseases, 2016 , 75, A42.1-A42	2.4	
437	Targeted Based Treatment of Metastatic Castration-Resistant Prostate Cancer: Revolutionizing Systemic Radiotherapy?. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1838-1839	8.9	6
436	Targeting the Human Epidermal Growth Factor Receptors with Immuno-PET: Imaging Biomarkers from Bench to Bedside. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 996-1001	8.9	4

435	Comparison of Tumor Uptake Heterogeneity Characterization Between Static and Parametric 18F-FDG PET Images in Non-Small Cell Lung Cancer. <i>Journal of Nuclear Medicine</i> , 2016 , 57, 1033-9	8.9	25
434	A systematic review on [(18)F]FLT-PET uptake as a measure of treatment response in cancer patients. <i>European Journal of Cancer</i> , 2016 , 55, 81-97	7.5	81
433	Positron emission tomography response criteria in solid tumours criteria for quantitative analysis of [18F]-fluorodeoxyglucose positron emission tomography with integrated computed tomography for treatment response assessment in metastasised solid tumours: All that glitters is not gold.	7.5	5
432	Performance of automatic image segmentation algorithms for calculating total lesion glycolysis for early response monitoring in non-small cell lung cancer patients during concomitant chemoradiotherapy. <i>Radiotherapy and Oncology</i> , 2016 , 119, 473-9	5.3	12
431	FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 328-54	8.8	1446
430	FDG-PET/CT in a Patient with Poor-Risk Non-Seminoma Testis with Mature Teratoma and Secondary Gliosarcoma: Multimodality Imaging for Guiding Multimodality Treatment. <i>Nuclear Medicine and Molecular Imaging</i> , 2015 , 49, 237-40	1.9	5
429	IIIn-anti-F4/80-A3-1 antibody: a novel tracer to image macrophages. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 1430-8	8.8	20
428	Immuno-PET and Immuno-SPECT of Rheumatoid Arthritis with Radiolabeled Anti-Fibroblast Activation Protein Antibody Correlates with Severity of Arthritis. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 778-83	8.9	59
427	Molecular imaging of prostate cancer: tapping into the opportunities. <i>Journal of Nuclear Medicine</i> , 2015 , 56, 169-70	8.9	3
426	In response to "histopathologic validation of 3'-deoxy-3'-(18)F-fluorothymidine PET for detecting tumour repopulation during fractionated radiotherapy in human FaDu squamous cell carcinoma in nude mice". <i>Radiotherapy and Oncology</i> , 2015 , 114, 417-8	5.3	
425	Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts. <i>Molecular Imaging and Biology</i> , 2015 , 17, 94-101	3.8	11
424	Tumor and red bone marrow dosimetry: comparison of methods for prospective treatment planning in pretargeted radioimmunotherapy. <i>EJNMMI Physics</i> , 2015 , 2, 5	4.4	6
423	Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer. <i>PET Clinics</i> , 2015 , 10, 345-60	2.2	18
422	PET in the management of locally advanced and metastatic NSCLC. <i>Nature Reviews Clinical Oncology</i> , 2015 , 12, 395-407	19.4	52
421	Retrospective quality control review of FDG scans in the imaging sub-study of PALETTE EORTC 62072/VEG110727: a randomized, double-blind, placebo-controlled phase III trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2015 , 42, 848-57	8.8	21
420	The impact of respiratory gated positron emission tomography on clinical staging and management of patients with lung cancer. <i>Lung Cancer</i> , 2015 , 90, 217-23	5.9	15
419	Relationship of promising methods in the detection of anthracycline-induced cardiotoxicity in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2015 , 76, 957-67	3.5	19
418	Targeting human prostate cancer with 111In-labeled D2B IgG, F(ab')2 and Fab fragments in nude mice with PSMA-expressing xenografts. <i>Contrast Media and Molecular Imaging</i> , 2015 , 10, 28-36	3.2	26

417	Anakinra injection site reaction on FDG PET/CT. Clinical Nuclear Medicine, 2015, 40, 492-3	1.7	1
416	Update on F-18-fluoro-deoxy-glucose-PET/computed tomography in nonsmall cell lung cancer. <i>Current Opinion in Pulmonary Medicine</i> , 2015 , 21, 314-21	3	18
415	Upregulation of IGF-1R expression during neoadjuvant therapy predicts poor outcome in breast cancer patients. <i>PLoS ONE</i> , 2015 , 10, e0117745	3.7	27
414	Multimodality imaging to predict response to systemic treatment in patients with advanced colorectal cancer. <i>PLoS ONE</i> , 2015 , 10, e0120823	3.7	28
413	Optimization of Dual-Labeled Antibodies for Targeted Intraoperative Imaging of Tumors. <i>Molecular Imaging</i> , 2015 , 14, 7290.2015.00015	3.7	25
412	Noninvasive Imaging of Tumor PD-L1 Expression Using Radiolabeled Anti-PD-L1 Antibodies. <i>Cancer Research</i> , 2015 , 75, 2928-36	10.1	150
411	Imaging-Based Treatment Adaptation in Radiation Oncology. Journal of Nuclear Medicine, 2015, 56, 192	2289)	20
410	Radionuclide and Fluorescence Imaging of Clear Cell Renal Cell Carcinoma Using Dual Labeled Anti-Carbonic Anhydrase IX Antibody G250. <i>Journal of Urology</i> , 2015 , 194, 532-8	2.5	20
409	Abstract OT3-2-01: IMPACT: IMaging PAtients for Cancer drug selecTion IMetastatic breast cancer (MBC) 2015 ,		4
408	Tumor Targeting Using Radiolabeled Antibodies for Image-Guided Drug Delivery. <i>Current Drug Targets</i> , 2015 , 16, 625-33	3	5
408 407			
	Targets, 2015, 16, 625-33 Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody		
407	Targets, 2015, 16, 625-33 Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma <i>Journal of Clinical Oncology</i> , 2015, 33, e14 Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer.	40⁴1²4-e	14014
407	Targets, 2015, 16, 625-33 Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma Journal of Clinical Oncology, 2015, 33, e14 Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6 Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with	10 ¹⁷ 4-e	14014
407 406 405	Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma <i>Journal of Clinical Oncology</i> , 2015 , 33, e14. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2015 , 35, 5601-6 Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014 , 9, 339-47 Dynamics of IGF-1R expression during endocrine breast cancer treatment. <i>Molecular Imaging and</i>	4014-e 2.3 5	14014 2 25
407 406 405 404	Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma Journal of Clinical Oncology, 2015, 33, e14. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. Anticancer Research, 2015, 35, 5601-6 Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. Targeted Oncology, 2014, 9, 339-47 Dynamics of IGF-1R expression during endocrine breast cancer treatment. Molecular Imaging and Biology, 2014, 16, 529-37 Non-invasive quantification of the beta cell mass by SPECT with IIIIn-labelled exendin. Diabetologia,	40174-e 2.3 5 3.8	14014 2 25 4
407 406 405 404 403	Phase II study of Lutetium-177-labeled anti-Carbonic Anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma <i>Journal of Clinical Oncology</i> , 2015 , 33, e14. Biological Effects After Discontinuation of VEGFR Inhibitors in Metastatic Renal Cell Cancer. <i>Anticancer Research</i> , 2015 , 35, 5601-6 Temsirolimus and pegylated liposomal doxorubicin (PLD) combination therapy in breast, endometrial, and ovarian cancer: phase Ib results and prediction of clinical outcome with FDG-PET/CT. <i>Targeted Oncology</i> , 2014 , 9, 339-47 Dynamics of IGF-1R expression during endocrine breast cancer treatment. <i>Molecular Imaging and Biology</i> , 2014 , 16, 529-37 Non-invasive quantification of the beta cell mass by SPECT with IIIIn-labelled exendin. <i>Diabetologia</i> , 2014 , 57, 950-9 Anti-CEA antibody fragments labeled with [(18)F]AlF for PET imaging of CEA-expressing tumors.	4014-e 2.3 5 3.8	14014 2 25 4 116

399	Tyrosine kinase inhibitor sorafenib decreases 111In-girentuximab uptake in patients with clear cell renal cell carcinoma. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 242-7	8.9	26
398	Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2014 , 29, 323-9	3.9	26
397	Imaging the folate receptor on cancer cells with 99mTc-etarfolatide: properties, clinical use, and future potential of folate receptor imaging. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 701-4	8.9	55
396	Radionuclide imaging of drug delivery for patient selection in targeted therapy. <i>Expert Opinion on Drug Delivery</i> , 2014 , 11, 175-85	8	7
395	SPECT- and fluorescence image-guided surgery using a dual-labeled carcinoembryonic antigen-targeting antibody. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1519-24	8.9	31
394	Influence of experience and qualification on PET-based target volume delineation. When there is no expertask your colleague. <i>Strahlentherapie Und Onkologie</i> , 2014 , 190, 555-62	4.3	19
393	The EANM clinical and technical guidelines for lymphoscintigraphy and sentinel node localization in gynaecological cancers. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1463-77	8.8	60
392	Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1593-602	8.8	29
391	Response to comment by Aprile et al.: the EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 1259-60	8.8	5
390	Diagnostic value of FDG-PET/(CT) in children with fever of unknown origin and unexplained fever during immune suppression. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 191	6 ⁸ .8 6-23	27
389	Targeted radionuclide and fluorescence dual-modality imaging of cancer: preclinical advances and clinical translation. <i>Molecular Imaging and Biology</i> , 2014 , 16, 747-55	3.8	39
388	Optical Imaging of Renal Cell Carcinoma with Anti-Carbonic Anhydrase IX Monoclonal Antibody Girentuximab. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 1035-40	8.9	21
387	18F-FDG PET/CT for the Detection of Septic Embolisms in Patients with Infectious Endocarditis. Journal of Nuclear Medicine, 2014 , 55, 1045-6	8.9	4
386	Imaging integrin ⊞ on blood vessels with 111In-RGD2 in head and neck tumor xenografts. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 281-6	8.9	21
385	Dual-Modality Image-Guided Surgery of Prostate Cancer with a Radiolabeled Fluorescent Anti-PSMA Monoclonal Antibody. <i>Journal of Nuclear Medicine</i> , 2014 , 55, 995-1001	8.9	66
384	Cost-effectiveness of FDG-PET/CT for cytologically indeterminate thyroid nodules: a decision analytic approach. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, 3263-74	5.6	32
383	Cardiovascular and thrombogenic risk of decidual vasculopathy in preeclampsia. <i>American Journal of Obstetrics and Gynecology</i> , 2014 , 210, 545.e1-6	6.4	23
382	Preclinical studies of SPECT and PET tracers for NET. <i>PET Clinics</i> , 2014 , 9, 63-9	2.2	

381	Pretargeted imaging and radioimmunotherapy of cancer using antibodies and bioorthogonal chemistry. <i>Frontiers in Medicine</i> , 2014 , 1, 44	4.9	47	
380	18F-FLT PET changes during radiotherapy combined with cetuximab in head and neck squamous cell carcinoma patients. <i>Nuklearmedizin - NuclearMedicine</i> , 2014 , 53, 60-6	1.8	6	
379	Optimizing Lutetium 177Antitarbonic Anhydrase IX Radioimmunotherapy in an Intraperitoneal Clear Cell Renal Cell Carcinoma Xenograft Model. <i>Molecular Imaging</i> , 2014 , 13, 7290.2014.00008	3.7	10	
378	Amplitude-based optimal respiratory gating in positron emission tomography in patients with primary lung cancer. <i>European Radiology</i> , 2014 , 24, 3242-50	8	40	
377	Zirconium-89 labeled antibodies: a new tool for molecular imaging in cancer patients. <i>BioMed Research International</i> , 2014 , 2014, 203601	3	89	
376	mTOR Inhibition promotes TTF1-dependent redifferentiation and restores iodine uptake in thyroid carcinoma cell lines. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2014 , 99, E1368-75	5.6	28	
375	Cetuximab reduces the accumulation of radiolabeled bevacizumab in cancer xenografts without decreasing VEGF expression. <i>Molecular Pharmaceutics</i> , 2014 , 11, 4249-57	5.6	6	
374	Monitoring hypoxia and vasculature during bevacizumab treatment in a murine colorectal cancer model. <i>Contrast Media and Molecular Imaging</i> , 2014 , 9, 237-45	3.2	22	
373	Comparison of a free-breathing CT and an expiratory breath-hold CT with regard to spatial alignment of amplitude-based respiratory-gated PET and CT images. <i>Journal of Nuclear Medicine Technology</i> , 2014 , 42, 269-73	1.1	10	
372	Temsirolimus combined with cisplatin or bevacizumab is active in osteosarcoma models. <i>International Journal of Cancer</i> , 2014 , 135, 2770-82	7.5	17	
371	Contributions of multimodal imaging. <i>Cancer Imaging</i> , 2014 , 14,	5.6	78	
370	Glucose metabolism in NSCLC is histology-specific and diverges the prognostic potential of 18FDG-PET for adenocarcinoma and squamous cell carcinoma. <i>Journal of Thoracic Oncology</i> , 2014 , 9, 1485-93	8.9	78	
369	The influence of SPECT reconstruction algorithms on image quality and diagnostic accuracy in phantom measurements and 99mTc-sestamibi parathyroid scintigraphy. <i>Nuclear Medicine Communications</i> , 2014 , 35, 64-72	1.6	6	
368	Comparison of liver SUV using unenhanced CT versus contrast-enhanced CT for attenuation correction in (18)F-FDG PET/CT. <i>Nuclear Medicine Communications</i> , 2014 , 35, 472-7	1.6	7	
367	Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer. <i>Cancer Research</i> , 2014 , 74, 6216-23	10.1	19	
366	Theranostic applications of antibodies in oncology. <i>Molecular Oncology</i> , 2014 , 8, 799-812	7.9	46	
365	Assessing the response to targeted therapies in renal cell carcinoma: technical insights and practical considerations. <i>European Urology</i> , 2014 , 65, 766-77	10.2	30	
364	Semiautomatic methods for segmentation of the proliferative tumour volume on sequential FLT PET/CT images in head and neck carcinomas and their relation to clinical outcome. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014 , 41, 915-24	8.8	30	

363	PET/CT with 89Zr-trastuzumab and 18F-FDG to individualize treatment with trastuzumab emtansine (T-DM1) in metastatic HER2-positive breast cancer (mBC) <i>Journal of Clinical Oncology</i> , 2014 , 32, 11001-11001	2.2	10
362	Radiolabeled imaging probes targeting angiogenesis for personalized medicine. <i>Current Pharmaceutical Design</i> , 2014 , 20, 2293-307	3.3	3
361	In vivo imaging of therapy-induced anti-cancer immune responses in humans. <i>Cellular and Molecular Life Sciences</i> , 2013 , 70, 2237-57	10.3	17
360	The use of FDG-PET/CT in patients with febrile neutropenia. Seminars in Nuclear Medicine, 2013, 43, 340	-8.4	20
359	FDG-PET in fever of unknown origin. Seminars in Nuclear Medicine, 2013, 43, 333-9	5.4	51
358	The value of 18F-FDG PET/CT in diagnosing infectious endocarditis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1102-7	8.8	64
357	Reply to comment by Treglia and Bertagna: FDG PET/CT for detection of infectious endocarditis. European Journal of Nuclear Medicine and Molecular Imaging, 2013 , 40, 1114-5	8.8	1
356	Immunotherapy response evaluation with (18)F-FDG-PET in patients with advanced stage renal cell carcinoma. <i>World Journal of Urology</i> , 2013 , 31, 841-6	4	12
355	Molecular PET imaging for biology-guided adaptive radiotherapy of head and neck cancer. <i>Acta Oncolgica</i> , 2013 , 52, 1257-71	3.2	42
354	The EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1932-47	8.8	172
353	Localizing chronic Q fever: a challenging query. BMC Infectious Diseases, 2013, 13, 413	4	27
352	Pathology-based validation of FDG PET segmentation tools for volume assessment of lymph node metastases from head and neck cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 1828-35	8.8	24
351	Phase 1 radioimmunotherapy study with lutetium 177-labeled anti-carbonic anhydrase IX monoclonal antibody girentuximab in patients with advanced renal cell carcinoma. <i>European Urology</i> , 2013 , 64, 478-85	10.2	64
350	Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell carcinoma. <i>European Urology</i> , 2013 , 63, 1101-6	10.2	58
349	Imaging integrin alpha-v-beta-3 expression in tumors with an 18F-labeled dimeric RGD peptide. <i>Contrast Media and Molecular Imaging</i> , 2013 , 8, 238-45	3.2	30
348	Reply to John Samuel Banerji's letter to the editor re: Constantijn H.J. Muselaers, Otto C. Boerman, Egbert Oosterwijk, Johannes F. Langenhuijsen, Wim J.G. Oyen, Peter F.A. Mulders. Indium-111-labeled girentuximab immunoSPECT as a diagnostic tool in clear cell renal cell	10.2	
347	The strength of small: improved targeting of insulin-like growth factor-1 receptor (IGF-1R) with F(ab') IR 1507 fragments in Ewing sarcomas. <i>European Journal of Cancer</i> , 2013 , 49, 2851-8	7.5	9
346	Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. <i>Investigational New Drugs</i> , 2013 , 31, 881-90	4.3	7

345	18F-FLT PET during radiotherapy or chemoradiotherapy in head and neck squamous cell carcinoma is an early predictor of outcome. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 532-40	8.9	100
344	Natural human plasmacytoid dendritic cells induce antigen-specific T-cell responses in melanoma patients. <i>Cancer Research</i> , 2013 , 73, 1063-75	10.1	239
343	Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2013 , 40, 137	77-83	36
342	Individualized image-based lymph node irradiation for prostate cancer. <i>Nature Reviews Urology</i> , 2013 , 10, 376-85	5.5	9
341	Molecular imaging and carbonic anhydrase IX-targeted radioimmunotherapy in clear cell renal cell carcinoma. <i>Immunotherapy</i> , 2013 , 5, 489-95	3.8	13
340	Correlation between tumor oxygenation and 18F-fluoromisonidazole PET data simulated based on microvessel images. <i>Acta Oncolgica</i> , 2013 , 52, 1308-13	3.2	12
339	Targeting of 111In-labeled dendritic cell human vaccines improved by reducing number of cells. <i>Clinical Cancer Research</i> , 2013 , 19, 1525-33	12.9	41
338	Preoperative FDG-PET-scan in patients with resectable colorectal liver metastases does not improve overall survival: a retrospective analyses stratified by clinical risk score. <i>Digestive Surgery</i> , 2013 , 30, 451-8	2.5	9
337	Bevacizumab reduces tumor targeting of antiepidermal growth factor and anti-insulin-like growth factor 1 receptor antibodies. <i>International Journal of Cancer</i> , 2013 , 133, 307-14	7.5	42
336	ImmunoPET imaging of renal cell carcinoma with (124)I- and (89)Zr-labeled anti-CAIX monoclonal antibody cG250 in mice. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2013 , 28, 510-5	3.9	39
335	Reducing cell number improves the homing of dendritic cells to lymph nodes upon intradermal vaccination. <i>OncoImmunology</i> , 2013 , 2, e24661	7.2	16
334	18F-FDG PET early response evaluation of locally advanced non-small cell lung cancer treated with concomitant chemoradiotherapy. <i>Journal of Nuclear Medicine</i> , 2013 , 54, 1528-34	8.9	90
333	Tumor-receptor imaging in breast cancer: a tool for patient selection and response monitoring. <i>Current Molecular Medicine</i> , 2013 , 13, 1506-22	2.5	9
332	Improved labelling of DTPA- and DOTA-conjugated peptides and antibodies with 111In in HEPES and MES buffer. <i>EJNMMI Research</i> , 2012 , 2, 4	3.6	34
331	Pretargeted immuno-PET of CEA-expressing intraperitoneal human colonic tumor xenografts: a new sensitive detection method. <i>EJNMMI Research</i> , 2012 , 2, 5	3.6	19
330	Optimized labeling of NOTA-conjugated octreotide with F-18. <i>Tumor Biology</i> , 2012 , 33, 427-34	2.9	57
329	18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 120-8	8.8	40
328	Quantitative assessment of heterogeneity in tumor metabolism using FDG-PET. <i>International Journal of Radiation Oncology Biology Physics</i> , 2012 , 82, e725-31	4	29

327	PET of tumors expressing gastrin-releasing peptide receptor with an 18F-labeled bombesin analog. Journal of Nuclear Medicine, 2012 , 53, 947-52	8.9	60
326	Optimization of IGF-1R SPECT/CT imaging using 111In-labeled F(ab')2 and Fab fragments of the monoclonal antibody R1507. <i>Molecular Pharmaceutics</i> , 2012 , 9, 2314-21	5.6	29
325	Improved resistance to ischemia and reperfusion, but impaired protection by ischemic preconditioning in patients with type 1 diabetes mellitus: a pilot study. <i>Cardiovascular Diabetology</i> , 2012 , 11, 124	8.7	22
324	Tumour response prediction by diffusion-weighted MR imaging: ready for clinical use?. <i>Critical Reviews in Oncology/Hematology</i> , 2012 , 83, 194-207	7	52
323	Aberrant reward processing in Parkinson's disease is associated with dopamine cell loss. <i>NeuroImage</i> , 2012 , 59, 3339-46	7.9	46
322	Identification of residual metabolic-active areas within NSCLC tumours using a pre-radiotherapy FDG-PET-CT scan: a prospective validation. <i>Lung Cancer</i> , 2012 , 75, 73-6	5.9	89
321	3'-Deoxy-3'-18F-fluorothymidine PET-derived proliferative volume predicts overall survival in high-grade glioma patients. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1904-10	8.9	37
320	Insight into the dynamics, localization and magnitude of antigen-specific immune responses by [(18)F]FLT PET imaging. <i>Oncolmmunology</i> , 2012 , 1, 744-745	7.2	2
319	Reproducibility of functional volume and activity concentration in 18F-FDG PET/CT of liver metastases in colorectal cancer. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39, 1858-67	8.8	22
318	FDG-PET/CT based response-adapted treatment. <i>Cancer Imaging</i> , 2012 , 12, 324-35	5.6	16
317	Prospects in radionuclide imaging of prostate cancer. <i>Prostate</i> , 2012 , 72, 1262-72	4.2	25
316	Radiolabelled GLP-1 analogues for in vivo targeting of insulinomas. <i>Contrast Media and Molecular Imaging</i> , 2012 , 7, 160-6	3.2	39
315	Radiolabelled peptides for oncological diagnosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2012 , 39 Suppl 1, S78-92	8.8	66
314	Imaging of human epidermal growth factor receptor type 2 expression with 18F-labeled affibody molecule ZHER2:2395 in a mouse model for ovarian cancer. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 146-	53 ^{8.9}	58
313	Modelling and simulation of the influence of acute and chronic hypoxia on [18F]fluoromisonidazole PET imaging. <i>Physics in Medicine and Biology</i> , 2012 , 57, 1675-84	3.8	29
312	Dosimetric analysis of 177Lu-cG250 radioimmunotherapy in renal cell carcinoma patients: correlation with myelotoxicity and pretherapeutic absorbed dose predictions based on 111In-cG250 imaging. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 82-9	8.9	44
311	In vivo tracking techniques for cellular regeneration, replacement, and redirection. <i>Journal of Nuclear Medicine</i> , 2012 , 53, 1825-8	8.9	18
310	Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer. <i>Journal of Nuclear Medicine</i> 2012, 53, 1926-32	8.9	9

309	(18)F-FLT-PET for Response Evaluation of MEK Inhibitor Selumetinib (AZD6244, ARRY-142886) in Patients with Solid Tumors. <i>World Journal of Nuclear Medicine</i> , 2012 , 11, 65-9	0.6	7
308	Metastatic infectious disease and clinical outcome in Staphylococcus aureus and Streptococcus species bacteremia. <i>Medicine (United States)</i> , 2012 , 91, 86-94	1.8	65
307	Unexplained first trimester recurrent pregnancy loss and low venous reserves. <i>Human Reproduction</i> , 2012 , 27, 2613-8	5.7	8
306	18F-2-Deoxy-2-Fluoro-D-Glucose Positron Emission Tomography, Computed Tomography, and Magnetic Resonance Imaging for the Detection of Experimental Colorectal Liver Metastases. <i>Molecular Imaging</i> , 2012 , 11, 7290.2011.00035	3.7	2
305	False positive 18F-FDG PET/CT due to inflamed concha bullosa. Clinical Nuclear Medicine, 2012, 37, 509-	1 0 7	3
304	Cost-effectiveness of adding FDG-PET or CT to the diagnostic work-up of patients with stage III melanoma. <i>Annals of Surgery</i> , 2012 , 255, 771-6	7.8	39
303	Tumor hypoxia as a mechanism of resistance to bevacizumab in a murine model <i>Journal of Clinical Oncology</i> , 2012 , 30, e13111-e13111	2.2	1
302	Nuclear Medicine in the Assessment of Painful Joint Prostheses 2012 , 561-581		
301	The effect of bevacizumab on targeting of anti-epidermal growth factor receptor and anti-insulin-like growth factor 1 receptor antibodies <i>Journal of Clinical Oncology</i> , 2012 , 30, 3035-3035	2.2	O
300	Vascular and metabolic response to bevacizumab-containing regimens in two patients with colorectal liver metastases measured by dynamic contrast-enhanced MRI and dynamic 18F-FDG-PET. Clinical Colorectal Cancer, 2011 , 10, E1-5	3.8	12
299	Preclinical Evaluation of 68Ga-DOTA-Minigastrin for the Detection of Cholecystokinin-2/Gastrin Receptor-Positive Tumors. <i>Molecular Imaging</i> , 2011 , 10, 7290.2010.00032	3.7	16
298	Adjuvant radioimmunotherapy improves survival of rats after resection of colorectal liver metastases. <i>Annals of Surgery</i> , 2011 , 253, 336-41	7.8	10
297	Image quality phantom and parameters for high spatial resolution small-animal SPECT. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2011 , 654, 539-545	1.2	7
296	Scintigraphic techniques for early detection of cancer treatment-induced cardiotoxicity. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 560-71	8.9	73
295	Route of administration modulates the induction of dendritic cell vaccine-induced antigen-specific T cells in advanced melanoma patients. <i>Clinical Cancer Research</i> , 2011 , 17, 5725-35	12.9	138
294	PET imaging of Integrin expression in tumours with La-labelled mono-, di- and tetrameric RGD peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 128-37	8.8	93
293	Renal uptake of different radiolabelled peptides is mediated by megalin: SPECT and biodistribution studies in megalin-deficient mice. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 623-32	8.8	88
292	Can FDG PET predict radiation treatment outcome in head and neck cancer? Results of a prospective study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1449-58	8.8	65

291	Comparative biodistribution of 12 IIIn-labelled gastrin/CCK2 receptor-targeting peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2011 , 38, 1410-6	8.8	74
290	Pallidal dysfunction drives a cerebellothalamic circuit into Parkinson tremor. <i>Annals of Neurology</i> , 2011 , 69, 269-81	9.4	276
289	The role of [18F]-2-fluoro-2-deoxy-d-glucose-positron emission tomography in thyroid nodules with indeterminate fine-needle aspiration biopsy: systematic review and meta-analysis of the literature. <i>Cancer</i> , 2011 , 117, 4582-94	6.4	62
288	Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients. <i>International Journal of Cancer</i> , 2011 , 129, 507-12	7.5	110
287	Radiolabeled cetuximab: dose optimization for epidermal growth factor receptor imaging in a head-and-neck squamous cell carcinoma model. <i>International Journal of Cancer</i> , 2011 , 129, 870-8	7.5	44
286	PET-CT for radiotherapy treatment planning and response monitoring in solid tumors. <i>Nature Reviews Clinical Oncology</i> , 2011 , 8, 233-42	19.4	73
285	Characterization and optimization of image quality as a function of reconstruction algorithms and parameter settings in a Siemens Inveon small-animal PET scanner using the NEMA NU 4-2008 standards. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators,	1.2	16
284	Spectrometers, Detectors and Associated Equipment, 2011, 629, 357-367 Modelling and simulation of [18F]fluoromisonidazole dynamics based on histology-derived microvessel maps. <i>Physics in Medicine and Biology</i> , 2011, 56, 2045-57	3.8	51
283	Clinical applications of positron emission tomography in sarcoma management. <i>Expert Review of Anticancer Therapy</i> , 2011 , 11, 195-204	3.5	14
282	Imaging of prostate cancer with immuno-PET and immuno-SPECT using a radiolabeled anti-EGP-1 monoclonal antibody. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1601-7	8.9	25
281	PL - 92. Non-invasive determination of the beta cell mass in rats by SPECT with In-111-DTPA-Exendin-3. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011 , 9, 154-155	O	
280	State-of-the-art uroradiologic imaging in the diagnosis of prostate cancer. <i>Acta Oncolgica</i> , 2011 , 50 Suppl 1, 25-38	3.2	26
279	Shortened dynamic (18)F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1330; author reply 1330-1	8.9	1
278	Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET). <i>Oncologist</i> , 2011 , 16, 980-91	5.7	14
277	Predicting IGF-1R therapy response in bone sarcomas: immuno-SPECT imaging with radiolabeled R1507. <i>Clinical Cancer Research</i> , 2011 , 17, 7693-703	12.9	37
276	Cost-effectiveness of routine (18)F-FDG PET/CT in high-risk patients with gram-positive bacteremia. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1673-8	8.9	72
275	Using the NEMA NU 4 PET image quality phantom in multipinhole small-animal SPECT. <i>Journal of Nuclear Medicine</i> , 2011 , 52, 1646-53	8.9	23
274	Early identification of antigen-specific immune responses in vivo by [18F]-labeled 3'-fluoro-3'-deoxy-thymidine ([18F]FLT) PET imaging. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011 , 108, 18396-9	11.5	56

273	Preclinical evaluation of 68Ga-DOTA-minigastrin for the detection of cholecystokinin-2/gastrin receptor-positive tumors. <i>Molecular Imaging</i> , 2011 , 10, 144-52	3.7	9
272	Image-quality assessment for several positron emitters using the NEMA NU 4-2008 standards in the Siemens Inveon small-animal PET scanner. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 610-7	8.9	123
271	Renal toxicity of radiolabeled peptides and antibody fragments: mechanisms, impact on radionuclide therapy, and strategies for prevention. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1049-58	8.9	191
270	Pretargeted immuno-positron emission tomography imaging of carcinoembryonic antigen-expressing tumors with a bispecific antibody and a 68Ga- and 18F-labeled hapten peptide in mice with human tumor xenografts. <i>Molecular Cancer Therapeutics</i> , 2010 , 9, 1019-27	6.1	77
269	Imaging of inflammation by PET, conventional scintigraphy, and other imaging techniques. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1937-49	8.9	196
268	Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1780-7	8.9	45
267	ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled antibody R1507 in a triple-negative breast cancer model. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1565-72	8.9	77
266	SUV: from silly useless value to smart uptake value. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 173-5	8.9	35
265	Histopathologic validation of 3'-deoxy-3'-18F-fluorothymidine PET in squamous cell carcinoma of the oral cavity. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 713-9	8.9	21
264	PET of hypoxia with 89Zr-labeled cG250-F(ab')2 in head and neck tumors. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1076-83	8.9	90
263	111In-bevacizumab imaging of renal cell cancer and evaluation of neoadjuvant treatment with the vascular endothelial growth factor receptor inhibitor sorafenib. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1707-15	8.9	38
262	Innovations in radiotherapy planning of head and neck cancers: role of PET. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 66-76	8.9	68
261	Correlation of segmented metabolic tumor volume with outcomeletter. <i>Clinical Cancer Research</i> , 2010 , 16, 1968; author reply 1968-9	12.9	
2 60	18F-FDG PET/CT for detection of metastatic infection in gram-positive bacteremia. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 1234-40	8.9	96
259	A novel facile method of labeling octreotide with (18)F-fluorine. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 454-61	8.9	165
258	Bone scintigraphy after osteochondral autograft transplantation in the knee: 13 patients followed for 4 years. <i>Monthly Notices of the Royal Astronomical Society: Letters</i> , 2010 , 81, 206-10	4.3	9
257	Imaging of HIV-associated Kaposi sarcoma; F-18-FDG-PET/CT and In-111-bevacizumabscintigraphy. Journal of Acquired Immune Deficiency Syndromes (1999), 2010, 54, 444-6	3.1	13
256	18F-FLT PET/CT for early response monitoring and dose escalation in oropharyngeal tumors. <i>Journal of Nuclear Medicine</i> , 2010 , 51, 866-74	8.9	134

255	Stabilized (111)in-labeled sCCK8 analogues for targeting CCK2-receptor positive tumors: synthesis and evaluation. <i>Bioconjugate Chemistry</i> , 2010 , 21, 663-70	6.3	20
254	Clinical evidence on PET-CT for radiation therapy planning in head and neck tumours. <i>Radiotherapy and Oncology</i> , 2010 , 96, 328-34	5.3	69
253	PET and SPECT in osteomyelitis and prosthetic bone and joint infections: a systematic review. <i>Seminars in Nuclear Medicine</i> , 2010 , 40, 3-15	5.4	149
252	PET-CT for response assessment and treatment adaptation in head and neck cancer. <i>Lancet Oncology, The</i> , 2010 , 11, 661-9	21.7	93
251	Bone-marrow uptake of (18)F-FDG during fever. <i>Lancet Infectious Diseases, The</i> , 2010 , 10, 509-10; author reply 510-1	25.5	6
250	Development of radiotracers for the determination of the beta-cell mass in vivo. <i>Current Pharmaceutical Design</i> , 2010 , 16, 1561-7	3.3	40
249	Nodular fasciitis on F-18 FDG PET. <i>Clinical Nuclear Medicine</i> , 2010 , 35, 830-1	1.7	5
248	Added value of positron emission tomography imaging in the surgical treatment of colorectal liver metastases. <i>Nuclear Medicine Communications</i> , 2010 , 31, 938-44	1.6	28
247	Albumin-derived peptides efficiently reduce renal uptake of radiolabelled peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 226-34	8.8	35
246	FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 181-200	8.8	959
245	Methodological considerations in quantification of oncological FDG PET studies. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1408-25	8.8	96
244	68Ga-labelled exendin-3, a new agent for the detection of insulinomas with PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1345-55	8.8	117
243	(18)F-FDG PET patterns and BAL cell profiles in pulmonary sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1181-8	8.8	32
242	111In-pentetreotide scintigraphy: procedure guidelines for tumour imaging. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 1441-8	8.8	128
241	The role of (18)F-FDG PET in the differentiation between lung metastases and synchronous second primary lung tumours. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 2037-47	8.8	30
240	Procedure guidelines for PET/CT tumour imaging with 68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga-DOTA-NOC, 68Ga-DOTA-TATE. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2010 , 37, 2004-10	8.8	320
239	F-18-fluorodeoxyglucose positron emission tomography combined with CT in critically ill patients with suspected infection. <i>Intensive Care Medicine</i> , 2010 , 36, 504-11	14.5	48
238	Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy. <i>European Urology</i> , 2010 , 58, 75-83	10.2	153

(2009-2010)

237	Pretargeted radioimmunoscintigraphy in patients with primary colorectal cancer using a bispecific anticarcinoembryonic antigen CEA X anti-di-diethylenetriaminepentaacetic acid F(ab')2 antibody. <i>Cancer</i> , 2010 , 116, 1111-7	6.4	17
236	Scanning multiple mice in a small-animal PET scanner: Influence on image quality. <i>Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment</i> , 2010 , 621, 605-610	1.2	12
235	(18)F-fluoro-L-thymidine-PET for the evaluation of primary brain tumours in children: a report of three cases. <i>Nuclear Medicine Communications</i> , 2010 , 31, 482-7	1.6	8
234	Can antibody galactosylation be used to improve radioimmunotherapy of induced peritoneal carcinomatosis of colonic origin in the rat?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009 , 24, 29-34	₄ 3.9	3
233	Molecular imaging of solid tumors: exploiting the potential. <i>Nature Reviews Clinical Oncology</i> , 2009 , 6, 609-11	19.4	7
232	In situ expression of tumor antigens by messenger RNA-electroporated dendritic cells in lymph nodes of melanoma patients. <i>Cancer Research</i> , 2009 , 69, 2927-34	10.1	49
231	Limited amounts of dendritic cells migrate into the T-cell area of lymph nodes but have high immune activating potential in melanoma patients. <i>Clinical Cancer Research</i> , 2009 , 15, 2531-40	12.9	152
230	Endotoxin tolerance does not limit mild ischemia-reperfusion injury in humans in vivo. <i>Innate Immunity</i> , 2009 , 15, 360-7	2.7	9
229	A curve-fitting approach to estimate the arterial plasma input function for the assessment of glucose metabolic rate and response to treatment. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1933-9	8.9	52
228	Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment. <i>Journal of Clinical Oncology</i> , 2009 , 27, 4774-80	2.2	72
227	Exercise-induced changes in venous vascular function in nonpregnant formerly preeclamptic women. <i>Reproductive Sciences</i> , 2009 , 16, 414-20	3	10
226	Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. <i>Arteriosclerosis, Thrombosis, and Vascular Biology,</i> 2009 , 29, 963-8	9.4	33
225	Long-term outcome of biopsy-proven, frequently relapsing minimal-change nephrotic syndrome in children. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2009 , 4, 1593-600	6.9	98
224	Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1036-41	8.9	138
223	Reply: Increased Metabolic Activity of Indolent Liver Metastases After Resection of a Primary Colorectal Tumor 2009 , 50, 168.1-168		
222	Chemotherapy response monitoring of colorectal liver metastases by dynamic Gd-DTPA-enhanced MRI perfusion parameters and 18F-FDG PET metabolic rate. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 1777	-84	25
221	Spatial resolution and sensitivity of the Inveon small-animal PET scanner. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 139-47	8.9	159
220	18F-FDG and 18F-FLT do not discriminate between reactive and metastatic lymph nodes in oral cancer. <i>Journal of Nuclear Medicine</i> , 2009 , 50, 490-1	8.9	11

219	18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009 , 36, 1131-7	8.8	58
218	Role of radiography, MRI and FDG-PET/CT in diagnosing, staging and therapeutical evaluation of patients with multiple myeloma. <i>Annals of Hematology</i> , 2009 , 88, 1161-8	3	93
217	Contribution of normalization to image noise for the Siemens Inveon small-animal PET scanner. Nuclear Instruments and Methods in Physics Research, Section A: Accelerators, Spectrometers, Detectors and Associated Equipment, 2009, 605, 433-435	1.2	4
216	Radioimmunotherapy improves survival of rats with microscopic liver metastases of colorectal origin. <i>Annals of Surgical Oncology</i> , 2009 , 16, 2065-73	3.1	14
215	In-depth evaluation of the cycloadditionretro-DielsAlder reaction for in vivo targeting with [(111)In]-DTPA-RGD conjugates. <i>Nuclear Medicine and Biology</i> , 2009 , 36, 749-57	2.1	20
214	New targeted probes for radioimaging of angiogenesis. <i>Methods</i> , 2009 , 48, 188-92	4.6	34
213	Tc-99m-PEG-liposomes target both adhesions and abscesses and their reduction by hyaluronate in rats with fecal peritonitis. <i>Journal of Surgical Research</i> , 2009 , 154, 246-51	2.5	11
212	Monitoring and predicting response to therapy with 18F-FDG PET in colorectal cancer: a systematic review. <i>Journal of Nuclear Medicine</i> , 2009 , 50 Suppl 1, 43S-54S	8.9	173
211	Can FDG-PET assist in radiotherapy target volume definition of metastatic lymph nodes in head-and-neck cancer?. <i>Radiotherapy and Oncology</i> , 2009 , 91, 95-100	5.3	40
210	Fever of unknown origin. Seminars in Nuclear Medicine, 2009, 39, 81-7	5.4	65
209	Tumor accumulation of radiolabeled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2009 , 24, 195-200	3.9	20
208	Evaluation of different normalization procedures for the calculation of the standardized uptake value in therapy response monitoring studies. <i>Nuclear Medicine Communications</i> , 2009 , 30, 550-7	1.6	13
207	The PI3-K/AKT-pathway and radiation resistance mechanisms in non-small cell lung cancer. <i>Journal of Thoracic Oncology</i> , 2009 , 4, 761-7	8.9	106
206	The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. <i>HIV Medicine</i> , 2008 , 9, 771-9	2.7	28
205	Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: Lack of correlation with VEGF-A expression. <i>European Journal of Cancer</i> , 2008 , 44, 1835-40	7.5	55
204	Screening for distant metastases in head and neck cancer patients by chest CT or whole body FDG-PET: a prospective multicenter trial. <i>Radiotherapy and Oncology</i> , 2008 , 87, 221-9	5.3	87
204		5.3	27

(2008-2008)

201	Increased metabolic activity of indolent liver metastases after resection of a primary colorectal tumor. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 887-91	8.9	40
200	Comparison of tumor volumes derived from glucose metabolic rate maps and SUV maps in dynamic 18F-FDG PET. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 892-8	8.9	40
199	Carbonic anhydrase IX expression in clear cell renal cell carcinoma and normal tissues: experiences from (radio) immunotherapy. <i>Journal of Clinical Oncology</i> , 2008 , 26, 3808-9; author reply 3811-2	2.2	13
198	Intratumoral spatial distribution of hypoxia and angiogenesis assessed by 18F-FAZA and 125I-gluco-RGD autoradiography. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 1732; author reply 1732-3	8.9	2
197	The relation between venous reserve capacity and low plasma volume. <i>Reproductive Sciences</i> , 2008 , 15, 604-12	3	11
196	Multimodality probes: amphibian cars for molecular imaging. <i>Journal of Nuclear Medicine</i> , 2008 , 49, 1213	3849	15
195	In vivo imaging of abdominal aortic aneurysms: increased FDG uptake suggests inflammation in the aneurysm wall. <i>Journal of Endovascular Therapy</i> , 2008 , 15, 462-7	2.5	77
194	Hyperthermia and fibrinolytic therapy do not improve the beneficial effect of radioimmunotherapy following cytoreductive surgery in rats with peritoneal carcinomatosis of colorectal origin. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008 , 23, 301-9	3.9	7
193	Shortened dynamic FDG-PET protocol to determine the glucose metabolic rate in non-small cell lung carcinoma 2008 ,		3
192	Intracavitary radioimmunotherapy to treat solid tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2008 , 23, 92-107	3.9	20
191	Utility of fluorodeoxyglucose-PET in patients with differentiated thyroid carcinoma. <i>Nuclear Medicine Communications</i> , 2008 , 29, 636-41	1.6	21
190	Predictive and prognostic value of FDG-PET. Cancer Imaging, 2008, 8, 70-80	5.6	40
189	Thyroid Cancer: 18F-FDG-Positron Emission Tomography 2008 , 687-697		
188	Promises and challenges of positron emission tomography for assessment of sarcoma in daily clinical practice. <i>Cancer Imaging</i> , 2008 , 8 Spec No A, S61-8	5.6	10
187	Targeting of a CCK(2) receptor splice variant with (111)In-labelled cholecystokinin-8 (CCK8) and (111)In-labelled minigastrin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 386-	. <mark>82</mark> 8	35
186	Correlation of [18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 1803-11	8.8	77
185	The Netherlands protocol for standardisation and quantification of FDG whole body PET studies in multi-centre trials. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2008 , 35, 2320-33	8.8	298
184	Specific imaging of VEGF-A expression with radiolabeled anti-VEGF monoclonal antibody. <i>International Journal of Cancer</i> , 2008 , 122, 2310-4	7.5	52

183	Biological correlates of FDG uptake in non-small cell lung cancer. <i>Lung Cancer</i> , 2007 , 55, 79-87	5.9	146
182	The role of FDG-PET in the selection of patients with colorectal liver metastases. <i>Annals of Surgical Oncology</i> , 2007 , 14, 771-9	3.1	24
181	Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. <i>Annals of Surgical Oncology</i> , 2007 , 14, 818-26	3.1	59
180	18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 726-35	8.9	132
179	Multi-modality nuclear medicine imaging: artefacts, pitfalls and recommendations. <i>Cancer Imaging</i> , 2007 , 7, 77-83	5.6	17
178	Radiolabeled antibodies in renal cell carcinoma. <i>Cancer Imaging</i> , 2007 , 7, 179-88	5.6	20
177	Alpha v beta 3 integrin-targeting of intraperitoneally growing tumors with a radiolabeled RGD peptide. <i>International Journal of Cancer</i> , 2007 , 120, 605-10	7.5	53
176	Predictive and prognostic value of FDG-PET in nonsmall-cell lung cancer: a systematic review. <i>Cancer</i> , 2007 , 110, 1654-64	6.4	126
175	Gastroparesis in patients with inactive Crohn's disease: a case series. <i>BMC Gastroenterology</i> , 2007 , 7, 11	3	18
174	Timing of adjuvant radioimmunotherapy after cytoreductive surgery in experimental peritoneal carcinomatosis of colorectal origin. <i>Annals of Surgical Oncology</i> , 2007 , 14, 533-40	3.1	20
173	Comparison between local ablative therapy and chemotherapy for non-resectable colorectal liver metastases: a prospective study. <i>Annals of Surgical Oncology</i> , 2007 , 14, 1161-9	3.1	50
172	A comparison between radioimmunotherapy and hyperthermic intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis of colonic origin in rats. <i>Annals of Surgical Oncology</i> , 2007 , 14, 3274-82	3.1	39
171	Gender differences in Parkinson's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2007 , 78, 819-24	5.5	409
170	Improved targeting of the alpha(v)beta (3) integrin by multimerisation of RGD peptides. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 267-73	8.8	182
169	Quantification of FDG PET studies using standardised uptake values in multi-centre trials: effects of image reconstruction, resolution and ROI definition parameters. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 392-404	8.8	235
168	Software package for integrated data processing for internal dose assessment in nuclear medicine (SPRIND). European Journal of Nuclear Medicine and Molecular Imaging, 2007, 34, 413-21	8.8	15
167	FDG-PET/CT can visualise the extent of inflammation in rheumatoid arthritis of the tarsus. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 439	8.8	16
166	A prospective multi-centre study of the value of FDG-PET as part of a structured diagnostic protocol in patients with fever of unknown origin. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 694-703	8.8	152

165	Clinical radionuclide therapy dosimetry: the quest for the "Holy Gray". <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 772-786	8.8	107
164	EANM procedure guideline for radio-immunotherapy for B-cell lymphoma with 90Y-radiolabelled ibritumomab tiuxetan (Zevalin). <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2007 , 34, 616-22	8.8	59
163	A response to Nanotechnology and the need for risk governance O. Renn & M.C. Roco, 2006. J. Nanoparticle Research 8(2): 153191. <i>Journal of Nanoparticle Research</i> , 2007 , 9, 1217-1220	2.3	3
162	Pulmonary sclerosing hemangioma detected by fluorodeoxyglucose positron emission tomography in familial adenomatous polyposis: report of a case. <i>Diseases of the Colon and Rectum</i> , 2007 , 50, 1987-9	1 ^{3.1}	14
161	Chemotherapy response evaluation with 18F-FDG PET in patients with non-small cell lung cancer. Journal of Nuclear Medicine, 2007 , 48, 1592-8	8.9	99
160	Extraperitoneal leakage as a possible explanation for failure of one-time intraperitoneal treatment in ovarian cancer. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2007 , 22, 508-14	3.9	5
159	Augmented hyperaemia and reduced tissue injury in response to ischaemia in subjects with the 34C > T variant of the AMPD1 gene. <i>European Heart Journal</i> , 2007 , 28, 1085-91	9.5	22
158	A prospective multicenter study on fever of unknown origin: the yield of a structured diagnostic protocol. <i>Medicine (United States)</i> , 2007 , 86, 26-38	1.8	230
157	Development and application of peptide-based radiopharmaceuticals. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2007 , 7, 543-51	2.2	36
156	Impact of Ge-68/Ga-68-based versus CT-based attenuation correction on PET. <i>Medical Physics</i> , 2007 , 34, 889-97	4.4	14
155	Indication for different mechanisms of kidney uptake of radiolabeled peptides. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 596-601	8.9	122
154	Evaluation of image registration in PET/CT of the liver and recommendations for optimized imaging. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 910-9	8.9	33
153	Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study. <i>Journal of Thoracic Oncology</i> , 2007 , 2, 1007-12	8.9	17
152	A novel iterative method for lesion delineation and volumetric quantification with FDG PET. <i>Nuclear Medicine Communications</i> , 2007 , 28, 485-93	1.6	94
151	Radionuclide therapy of cancer with radiolabeled antibodies. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2007 , 7, 335-43	2.2	17
150	Writer's cramp: restoration of striatal D2-binding after successful biofeedback-based sensorimotor training. <i>Parkinsonism and Related Disorders</i> , 2007 , 13, 170-3	3.6	28
149	Effects of linker variation on the in vitro and in vivo characteristics of an 111In-labeled RGD peptide. <i>Nuclear Medicine and Biology</i> , 2007 , 34, 29-35	2.1	70
148	PET imaging of infection with a HYNIC-conjugated LTB4 antagonist labeled with F-18 via hydrazone formation. <i>Nuclear Medicine and Biology</i> , 2007 , 34, 691-5	2.1	17

147	Regarding Davis et al.: Assessment of (18)F PET signals for automatic target volume definition in radiotherapy treatment planning. <i>Radiotherapy and Oncology</i> , 2007 , 83, 102-3; author reply 103	5.3	5
146	[(18)F]FDG accumulation in an experimental model of multistage progression of cholangiocarcinoma. <i>Hepatology Research</i> , 2007 , 37, 127-32	5.1	5
145	99mTc-labeled interleukin 8 for the scintigraphic detection of infection and inflammation: first clinical evaluation. <i>Journal of Nuclear Medicine</i> , 2007 , 48, 337-43	8.9	32
144	Ability of FDG-PET to detect all cancers in patients with familial adenomatous polyposis, and impact on clinical management. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 270-4	8.8	9
143	Detection of pacemaker and lead infection with FDG-PET. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 1245	8.8	24
142	Scintigraphic imaging of P-glycoprotein expression with a radiolabelled antibody. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 1266-72	8.8	6
141	Improved tumour detection by gastrin receptor scintigraphy in patients with metastasised medullary thyroid carcinoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2006 , 33, 127	7 § :8	80
140	Combination therapy using the cyclooxygenase-2 inhibitor Parecoxib and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. <i>Cancer Immunology, Immunotherapy</i> , 2006 , 55, 47-55	7.4	8
139	Bone SPECT reduces the number of unnecessary mandibular resections in patients with squamous cell carcinoma. <i>Oral Oncology</i> , 2006 , 42, 409-14	4.4	19
138	FDG-PET for prediction of survival of patients with metastatic colorectal carcinoma. <i>Annals of Oncology</i> , 2006 , 17, 1650-5	10.3	42
138		10.3	4 ² 73
	Oncology, 2006, 17, 1650-5 Commonly used imaging techniques for diagnosis and staging. Journal of Clinical Oncology, 2006,	2.2	
137	Oncology, 2006, 17, 1650-5 Commonly used imaging techniques for diagnosis and staging. Journal of Clinical Oncology, 2006, 24, 3234-44 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy	2.2	73
137 136	Oncology, 2006, 17, 1650-5 Commonly used imaging techniques for diagnosis and staging. Journal of Clinical Oncology, 2006, 24, 3234-44 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocrine-Related Cancer, 2006, 13, 1203 Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer	2.2 3 ⁵ 17	73
137 136 135	Commonly used imaging techniques for diagnosis and staging. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3234-44 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2006 , 13, 1203 Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006 , 21, 263-8 Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small	2.2 3.517 3.9	73 46 7
137 136 135	Oncology, 2006, 17, 1650-5 Commonly used imaging techniques for diagnosis and staging. Journal of Clinical Oncology, 2006, 24, 3234-44 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. Endocrine-Related Cancer, 2006, 13, 1203 Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 263-8 Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. Cancer Biotherapy and Radiopharmaceuticals, 2006, 21, 506-14 Synthesis and biological evaluation of potent alphaybeta3-integrin receptor antagonists. Nuclear	2.2 3.517 3.9 3.9	73 46 7
137 136 135 134	Commonly used imaging techniques for diagnosis and staging. <i>Journal of Clinical Oncology</i> , 2006 , 24, 3234-44 Added value of gastrin receptor scintigraphy in comparison to somatostatin receptor scintigraphy in patients with carcinoids and other neuroendocrine tumours. <i>Endocrine-Related Cancer</i> , 2006 , 13, 1203 Targeting of biliary cancer with radiolabeled chimeric monoclonal antibody CG250. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006 , 21, 263-8 Combination therapy using gemcitabine and radioimmunotherapy in nude mice with small peritoneal metastases of colonic origin. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2006 , 21, 506-14 Synthesis and biological evaluation of potent alphavbeta3-integrin receptor antagonists. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 953-61	2.2 3.517 3.9 3.9	73 46 7 11 41

(2006-2006)

129	Thrombogenicity and related biological properties of heparin bonded collagen coated polyester and human umbilical vein prosthetic vascular grafts. <i>Journal of Surgical Research</i> , 2006 , 134, 182-9	2.5	6
128	Noninvasive monitoring of colonic carcinogenesis: feasibility of [(18)F]FDG-PET in the azoxymethane model. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 245-8	2.1	18
127	Development of 111In-labeled tumor-associated antigen peptides for monitoring dendritic-cell-based vaccination. <i>Nuclear Medicine and Biology</i> , 2006 , 33, 453-8	2.1	13
126	FDG-PET in colorectal cancer. <i>Cancer Imaging</i> , 2006 , 6, S71-81	5.6	36
125	From anatomical to biological target volumes: the role of PET in radiation treatment planning. <i>Cancer Imaging</i> , 2006 , 6, S107-16	5.6	25
124	Nuclear medicine imaging and therapy of neuroendocrine tumours. <i>Cancer Imaging</i> , 2006 , 6, S178-84	5.6	9
123	Correction of an image size difference between positron emission tomography (PET) and computed tomography (CT) improves image fusion of dedicated PET and CT. <i>Nuclear Medicine Communications</i> , 2006 , 27, 515-9	1.6	5
122	Peritoneal Carcinomatosis of Colorectal Origin: Standard of Care. <i>Annals of Surgery</i> , 2006 , 244, 633-634	1 7.8	
121	Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. <i>Annals of Surgery</i> , 2006 , 243, 212-22	7.8	370
120	FDG-PET in the clinically negative neck in oral squamous cell carcinoma. <i>Laryngoscope</i> , 2006 , 116, 809-7	133.6	36
119	Level of fluorodeoxyglucose uptake predicts risk for recurrence in melanoma patients presenting with lymph node metastases. <i>Annals of Surgical Oncology</i> , 2006 , 13, 919-26	3.1	20
118	Blinded Mid-Treatment FDG-PET in Newly Diagnosed Aggressive Non-Hodgkin Lymphoma (NHL): First Results of a Prospective Multicenter Study <i>Blood</i> , 2006 , 108, 2400-2400	2.2	1
117	Imaging Infection and Inflammation 2006 , 113-126		5
116	Renal uptake of radiolabeled octreotide in human subjects is efficiently inhibited by succinylated gelatin. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 432-6	8.9	62
115	Gelatin-based plasma expander effectively reduces renal uptake of 111In-octreotide in mice and rats. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 528-33	8.9	62
114	18F-FDG PET reduces unnecessary hemithyroidectomies for thyroid nodules with inconclusive cytologic results. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 770-5	8.9	66
113	Comparison of image-derived and arterial input functions for estimating the rate of glucose metabolism in therapy-monitoring 18F-FDG PET studies. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 945-9	8.9	68
112	Radioimmunotherapy is an effective adjuvant treatment after cytoreductive surgery of experimental colonic peritoneal carcinomatosis. <i>Journal of Nuclear Medicine</i> , 2006 , 47, 1867-74	8.9	23

111	Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci. <i>Journal of Medicinal Chemistry</i> , 2005 , 48, 6442-53	8.3	6
110	FDG-PET in the detection of early pancreatic cancer in a BOP hamster model. <i>Nuclear Medicine and Biology</i> , 2005 , 32, 445-50	2.1	8
109	Leukocytes in Complex Regional Pain Syndrome type I. <i>Inflammation</i> , 2005 , 29, 182-6	5.1	19
108	Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. <i>Clinical Pharmacology and Therapeutics</i> , 2005 , 78, 52-9	6.1	39
107	Diagnosis of Candida lung abscesses by 18F-fluorodeoxyglucose positron emission tomography. <i>Clinical Microbiology and Infection</i> , 2005 , 11, 493-5	9.5	37
106	Magnetic resonance tracking of dendritic cells in melanoma patients for monitoring of cellular therapy. <i>Nature Biotechnology</i> , 2005 , 23, 1407-13	44.5	712
105	Decrease in circulating anti-angiogenic factors (angiostatin and endostatin) after surgical removal of primary colorectal carcinoma coincides with increased metabolic activity of liver metastases. <i>Surgery</i> , 2005 , 137, 246-9	3.6	47
104	The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases. <i>Cancer</i> , 2005 , 104, 2658-70	6.4	199
103	Influence of blood glucose level, age and fasting period on non-pathological FDG uptake in heart and gut. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 98-101	8.8	105
102	FDG-PET is able to detect pancreatic carcinoma in chronic pancreatitis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 399-404	8.8	86
101	Sliced alternating DICOM series: convenient visualisation of image fusion on PACS. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 247-8	8.8	4
100	Optimised PET reconstruction of the head and neck area: improved diagnostic accuracy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2005 , 32, 1276-82	8.8	28
99	Antibody-guided radiation therapy of cancer. Cancer and Metastasis Reviews, 2005, 24, 539-67	9.6	44
98	Colorectal cancer: the role of PET/CT in recurrence. <i>Cancer Imaging</i> , 2005 , 5 Spec No A, S143-9	5.6	23
97	Lack of efficacy of two consecutive treatments of radioimmunotherapy with 131I-cG250 in patients with metastasized clear cell renal cell carcinoma. <i>Journal of Clinical Oncology</i> , 2005 , 23, 6540-8	2.2	74
96	Gadopentetate dimeglumine and FDG uptake in liver metastases of colorectal carcinoma as determined with MR imaging and PET. <i>Radiology</i> , 2005 , 237, 181-8	20.5	18
95	Biodistribution and imaging of FDG in rats with LS174T carcinoma xenografts and focal Escherichia coli infection. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2005 , 20, 310-5	3.9	7
94	In vivo molecular prediction of carbonic anhydrase IX-G250MN expression on immunotherapy outcome in renal cancer. <i>Clinical Cancer Research</i> , 2005 , 11, 8886; author reply 8886	12.9	4

(2004-2005)

93	Radioimmunotherapy with [1311]cG250 in patients with metastasized renal cell cancer: dosimetric analysis and immunologic response. <i>Clinical Cancer Research</i> , 2005 , 11, 7178s-7186s	12.9	37	
92	Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. <i>Circulation</i> , 2005 , 111, 173-8	16.7	39	
91	2-(18F)-fluoro-2-deoxy-D-glucose positron emission tomography detects clinical relevant adenomas of the colon: a prospective study. <i>Journal of Clinical Oncology</i> , 2005 , 23, 3713-7	2.2	80	
90	Positive positron emission tomography scan in sarcoidosis and two challenging cases of metastatic cancer. CASE 1. Mediastinal sarcoidosis in a melanoma patient treated with interferon. <i>Journal of Clinical Oncology</i> , 2005 , 23, 8906-7	2.2	15	
89	Pretargeting with bispecific anti-renal cell carcinoma x anti-DTPA(In) antibody in 3 RCC models. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 495-501	8.9	31	
88	Imaging of infection and inflammation with an improved 99mTc-labeled LTB4 antagonist. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 1546-51	8.9	10	
87	18F-FDG PET in detecting metastatic infectious disease. <i>Journal of Nuclear Medicine</i> , 2005 , 46, 2014-9	8.9	52	
86	Role of FDG-PET in the diagnosis and management of lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 561-7	3.5	11	
85	Improved tumor targeting of radiolabeled RGD peptides using rapid dose fractionation. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 399-404	3.9	32	
84	Demineralized bone matrix-induced ectopic bone formation in rats: in vivo study with follow-up by magnetic resonance imaging, magnetic resonance angiography, and dual-energy X-ray absorptiometry. <i>Tissue Engineering</i> , 2004 , 10, 747-54		12	
83	[18F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. <i>Clinical Cancer Research</i> , 2004 , 10, 6456-9	12.9	37	
82	Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases. <i>Expert Review of Anticancer Therapy</i> , 2004 , 4, 607-13	3.5	15	
81	Tracers to monitor the response to chemotherapy: in vitro screening of four radiopharmaceuticals. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 457-65	3.9	2	
8o	Striatal dopamine and learning strategy-an (123)I-FP-CIT SPECT study. <i>Neuropsychologia</i> , 2004 , 42, 1071	I- <u>8</u> .2	18	
79	Fever of unknown origin: prospective comparison of diagnostic value of (18)F-FDG PET and (111)In-granulocyte scintigraphy. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31, 1342-3; author reply 1344	8.8	11	
78	Clinical value of FDG PET in patients with fever of unknown origin and patients suspected of focal infection or inflammation. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2004 , 31, 29-37	8.8	196	
77	Two technetium-99m-labeled cholecystokinin-8 (CCK8) peptides for scintigraphic imaging of CCK receptors. <i>Bioconjugate Chemistry</i> , 2004 , 15, 561-8	6.3	39	
76	PET radioimmunoscintigraphy of renal cell cancer using 89Zr-labeled cG250 monoclonal antibody in nude rats. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 155-63	3.9	57	

75	Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 466-77	3.9	11
74	Solitary skull recurrence from stage I seminomatous germ cell tumor of testis. <i>Urology</i> , 2004 , 64, 377-9	1.6	3
73	Fluorine 18 fluorodeoxyglucose positron emission tomography in the diagnosis and follow-up of three patients with vasculitis. <i>American Journal of Medicine</i> , 2004 , 116, 50-3	2.4	34
7 ²	99mTc-labeled interleukin-8 for scintigraphic detection of pulmonary infections. <i>Chest</i> , 2004 , 126, 1954	-6 .13	16
71	Pharmacokinetics and Tumor Targeting of 131I-Labeled F(ab')2 Fragments of the Chimeric Monoclonal Antibody G250: Preclinical and Clinical Pilot Studies. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2004 , 19, 466-477	3.9	19
70	PET/CT: panacea, redundancy, or something in between?. <i>Journal of Nuclear Medicine</i> , 2004 , 45 Suppl 1, 15S-24S	8.9	14
69	Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re. <i>Journal of Nuclear Medicine</i> , 2004 , 45, 327-37	8.9	99
68	Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. <i>Journal of Nuclear Medicine</i> , 2004 , 45, 1224-32	8.9	52
67	Normal bone mineral density and lean body mass, but increased fat mass, in young adult patients with congenital adrenal hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003 , 88, 1036-42	5.6	105
66	Evaluation of Tc-99m-labeled glycoprotein IIb/IIIa receptor antagonist DMP444 SPECT in patients with infective endocarditis. <i>Clinical Nuclear Medicine</i> , 2003 , 28, 480-4	1.7	8
65	FDG-PET in infectious and inflammatory disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2003 , 30, 1568-70	8.8	14
64	Diagnosis of renal and hepatic cyst infections by 18-F-fluorodeoxyglucose positron emission tomography in autosomal dominant polycystic kidney disease. <i>American Journal of Kidney Diseases</i> , 2003 , 41, E18-21	7.4	70
63	Experimental radioimmunotherapy of small peritoneal metastases of colorectal origin. <i>International Journal of Cancer</i> , 2003 , 106, 965-72	7.5	33
62	Analysis of dendritic cell trafficking using EGFP-transgenic mice. <i>Immunology Letters</i> , 2003 , 89, 17-24	4.1	41
61	Nuclear medicine imaging to predict response to radiotherapy: a review. <i>International Journal of Radiation Oncology Biology Physics</i> , 2003 , 55, 5-15	4	66
60	Interferons can upregulate the expression of the tumor associated antigen G250-MN/CA IX, a potential target for (radio)immunotherapy of renal cell carcinoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003 , 18, 539-47	3.9	18
59	Biodistribution of 131I-, 186Re-, 177Lu-, and 88Y-labeled hLL2 (Epratuzumab) in nude mice with CD22-positive lymphoma. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2003 , 18, 525-33	3.9	24
58	Molecular Imaging of Infection and Inflammation 2003 , 233-251		

(2001-2003)

57	Effective migration of antigen-pulsed dendritic cells to lymph nodes in melanoma patients is determined by their maturation state. <i>Cancer Research</i> , 2003 , 63, 12-7	10.1	333
56	Pretargeted radioimmunotherapy of cancer: progress step by step. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 400-11	8.9	147
55	Administration guidelines for radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-labeled anti-CD20 monoclonal antibody. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 853	8.9	3
54	A bivalent leukotriene B(4) antagonist for scintigraphic imaging of infectious foci. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 1087-91	8.9	16
53	Kinetics of 99mTc-labeled interleukin-8 in experimental inflammation and infection. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 1502-9	8.9	17
52	Targeting of metastatic renal cell carcinoma with the chimeric monoclonal antibody G250 labeled with (131)I or (111)In: an intrapatient comparison. <i>Clinical Cancer Research</i> , 2003 , 9, 3953S-60S	12.9	41
51	Final results of a phase I radioimmunotherapy trial using (186)Re-epratuzumab for the treatment of patients with non-Hodgkin's lymphoma. <i>Clinical Cancer Research</i> , 2003 , 9, 3995S-4002S	12.9	20
50	Dosimetric analysis of radioimmunotherapy with 186Re-labeled bivatuzumab in patients with head and neck cancer. <i>Journal of Nuclear Medicine</i> , 2003 , 44, 1690-9	8.9	23
49	Fluorinated amino acids for tumour imaging with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 681-90	8.8	135
48	Fluorinated amino acids for tumour imaging with positron emission tomography. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2002 , 29, 834-834	8.8	36
47	The role of (18)fluoro-2-deoxyglucose positron emission tomography in initial staging and re-staging after chemotherapy for testicular germ cell tumours. <i>BJU International</i> , 2002 , 89, 549-56	5.6	112
46	Comparison of a monomeric and dimeric radiolabeled RGD-peptide for tumor targeting. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2002 , 17, 641-6	3.9	142
45	Effects of coligand variation on the in vivo characteristics of Tc-99m-labeled interleukin-8 in detection of infection. <i>Bioconjugate Chemistry</i> , 2002 , 13, 370-7	6.3	34
44	Assessment of prosthetic vascular graft thrombogenicity using the technetium-99m labeled glycoprotein IIb/IIIa receptor antagonist DMP444 in a dog model. <i>Vascular</i> , 2002 , 10, 566-9		9
43	Scintigraphic imaging using 99mTc-labeled PEG liposomes allows early detection of experimental invasive pulmonary aspergillosis in neutropenic rats. <i>Nuclear Medicine and Biology</i> , 2002 , 29, 177-84	2.1	16
42	Heme is a potent inducer of inflammation in mice and is counteracted by heme oxygenase. <i>Blood</i> , 2001 , 98, 1802-11	2.2	324
41	Between the Scylla and Charybdis of peptide radionuclide therapy: hitting the tumor and saving the kidney. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 1447-9	8.8	33
40	Effect of subtotal colectomy on gastric emptying of a solid meal in slow-transit constipation. <i>Diseases of the Colon and Rectum</i> , 2001 , 44, 1189-95	3.1	20

39	Microscopic localization of PEG-liposomes in a rat model of focal infection. <i>Journal of Controlled Release</i> , 2001 , 75, 347-55	11.7	43
38	In vivo efficacy of trovafloxacin against Bacteroides fragilis in mixed infection with either Escherichia coli or a vancomycin-resistant strain of Enterococcus faecium in an established-abscess murine model. <i>Antimicrobial Agents and Chemotherapy</i> , 2001 , 45, 1394-401	5.9	16
37	Imaging infection/inflammation in the new millennium. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2001 , 28, 241-52		143
36	Radiopharmaceuticals to image infection and inflammation. Seminars in Nuclear Medicine, 2001, 31, 286	5- <u>95</u> 4	69
35	The effect of molecular weight on nonspecific accumulation of (99m)T-labeled proteins in inflammatory foci. <i>Nuclear Medicine and Biology</i> , 2001 , 28, 401-8	2.1	18
34	In Vivo Applications of PEG Liposomes: Unexpected Observations. <i>Critical Reviews in Therapeutic Drug Carrier Systems</i> , 2001 , 18, 16	2.8	57
33	Subcutaneous administration of superoxide dismutase entrapped in long circulating liposomes: in vivo fate and therapeutic activity in an inflammation model. <i>Pharmaceutical Research</i> , 2000 , 17, 600-6	4.5	34
32	Scintigraphic detection of acute experimental endocarditis with the technetium-99m labelled glycoprotein IIb/IIIa receptor antagonist DMP444. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2000 , 27, 392-9	8.8	19
31	Lyophilization of TC-99m-Hynic Labeled Peg-Liposomes. <i>Journal of Liposome Research</i> , 2000 , 10, 117-12	296.1	9
30	Pretargeted radioimmunotherapy of non-Hodgkin's lymphoma: best of both worlds?. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , 2000 , 15, 1-5	3.9	1
29	Radio-labeled receptor-binding peptides: a new class of radiopharmaceuticals. <i>Seminars in Nuclear Medicine</i> , 2000 , 30, 195-208	5.4	55
28	Labeling proteins with Tc-99m via hydrazinonicotinamide (HYNIC): optimization of the conjugation reaction. <i>Nuclear Medicine and Biology</i> , 2000 , 27, 599-604	2.1	30
27	Tc-99m-PEG-Liposomes for the evaluation of colitis in Crohn's disease. <i>Journal of Drug Targeting</i> , 2000 , 8, 225-33	5.4	56
26	Liposomes for scintigraphic detection of infection and inflammation. <i>Advanced Drug Delivery Reviews</i> , 1999 , 37, 225-235	18.5	60
25	Intravenous administration of superoxide dismutase entrapped in long circulating liposomes. II. In vivo fate in a rat model of adjuvant arthritis. <i>Biochimica Et Biophysica Acta - Biomembranes</i> , 1999 , 1419, 325-34	3.8	81
24	A comparison of free radical-induced vascular and skeletal muscle damage in immunocompetent and neutropenic rats. <i>Journal of Surgical Research</i> , 1999 , 82, 346-52	2.5	1
23	Imaging experimental intraabdominal abscesses with 99mTc-PEG liposomes and 99mTc-HYNIC IgG. <i>Annals of Surgery</i> , 1999 , 229, 551-7	7.8	27
22	Imaging of infection in rabbits with radioiodinated interleukin-1 (alpha and beta), its receptor antagonist and a chemotactic peptide: a comparative study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 347-52	8.8	32

21	Scintigraphic detection of infection and inflammation: new developments with special emphasis on receptor interaction. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1998 , 25, 535-46	8.8	31
20	Sterically Stabilized Liposomes to Image Infection and Inflammation 1998, 229-240		1
19	Acute myelofibrosis mimicking multiple bone metastases on Tc-99m MDP bone imaging. <i>Clinical Nuclear Medicine</i> , 1998 , 23, 1-2	1.7	5
18	Hip and knee arthroplasty infection. In-111-IgG scintigraphy in 102 cases. <i>Acta Orthopaedica</i> , 1997 , 68, 332-6		24
17	Organ damage is preceded by changes in protein extravasation in an experimental model of multiple organ dysfunction syndrome. <i>Shock</i> , 1997 , 7, 98-104	3.4	15
16	A novel animal model to evaluate oxygen derived free radical damage in soft tissue. <i>Free Radical Research</i> , 1997 , 26, 363-72	4	36
15	Soft tissue repair capacity after oxygen-derived free radical-induced damage in one hindlimb of the rat. <i>Journal of Surgical Research</i> , 1997 , 72, 60-9	2.5	18
14	Different behaviour of radioiodinated human recombinant interleukin-1 and its receptor antagonist in an animal model of infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 1531-5		23
13	Retention of technetium-99m in infectious foci in rats after release from technetium-99m labelled human non-specific polyclonal immunoglobulin G: a dual-label study with hydrazinonicotinamido and iminothiolano immunoglobulin. European Journal of Nuclear Medicine and Molecular Imaging,		15
12	1996, 23, 1536-9 Macrophage targeting in experimental arthritis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 727-9		
11	Technetium-99m labelled hydrazinonicotinamido human non-specific polyclonal immunoglobulin G for detection of infectious foci: a comparison with two other technetium-labelled immunoglobulin preparations. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 414-21		31
10	The uptake mechanisms of inflammation- and infection-localizing agents. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1996 , 23, 459-65		36
9	Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. <i>Journal of Leukocyte Biology</i> , 1996 , 60, 710-5	6.5	24
8	Dissociation of indium from indium-111-labelled diethylene triamine penta-acetic acid conjugated non-specific polyclonal human immunoglobulin G in inflammatory foci. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995 , 22, 212-9		24
7	Serial indium-111-labelled IgG biodistribution in rat Pneumocystis carinii pneumonia: a tool to monitor the course and severity of the infection. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995 , 22, 1129-32		2
6	Specific targeting of infectious foci with radioiodinated human recombinant interleukin-1 in an experimental model. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1995 , 22, 1249-55		41
5	Localization of infection in HIV antibody positive patients with fever. Comparison of the efficacy of Ga-67 citrate and radiolabeled human IgG. <i>Clinical Nuclear Medicine</i> , 1995 , 20, 334-9	1.7	7
4	Reflex sympathetic dystrophy of the hand: an excessive inflammatory response?. <i>Pain</i> , 1993 , 55, 151-1.	578	155

3	Specific antibody uptake in tuberculosis?. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 1993 , 20, 568-9		4
2	Radioimmunoconjugates in the detection of infection and inflammation. <i>Seminars in Nuclear Medicine</i> , 1993 , 23, 148-64	5.4	26
1	Indium-111-labeled human nonspecific immunoglobulin G: a new radiopharmaceutical for imaging infectious and inflammatory foci. <i>Clinical Infectious Diseases</i> , 1992 , 14, 1110-8	11.6	29